TB vaccine development: Where are we and why is it so difficult?

Thorax

Volumn 70, Issue 3, 2015, Pages 299-301

  Wilkie, Morven E M ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL IMMUNITY; CELLULAR IMMUNITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERANCE; FUNDING; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTOPOIESIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STUDY DESIGN; TH1 CELL; TH17 CELL; VACCINE PRODUCTION; IMMUNOLOGY; TUBERCULOSIS, PULMONARY;

DRUG DESIGN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84923130475     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-205202     Document Type: Article

References (5)

1. WHO. Global tuberculosis report 2013. World Health Organization, 2013.
2. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 2012;92(Supplement 1(0)):S6-13.
3. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381:1021-8.
4. McShane H, Williams A. A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data. Tuberculosis 2014;94:105-10.
5. Harris SA, Meyer J, Satti I, et al. Evaluation of a human BCG challenge model to assess anti-mycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination. J Infect Dis 2014;209:1259-68.